Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338870 · ClinicalTrials.gov registry record · Phase 2
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
NCT01338870 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 301 participants.
The verdict
NCT01338870, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
Study Summary
B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.
Interventions
- DRUG Placebo
- DRUG 150 mg PF-04991532
- DRUG 25 mg PF-04991532
- DRUG 75 mg PF-04991532
- DRUG 300 mg PF-04991532
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01338870
The ClinicalTrials.gov registry entry for NCT01338870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01338870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01338870 about?
NCT01338870 is a clinical study titled "Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes". B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be pl...
What is the current status of trial NCT01338870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2011-06. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01338870?
The interventions under investigation include: Placebo (DRUG), 150 mg PF-04991532 (DRUG), 25 mg PF-04991532 (DRUG), 75 mg PF-04991532 (DRUG), 300 mg PF-04991532 (DRUG).
Who is sponsoring clinical trial NCT01338870?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.